These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 11839581)

  • 21. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
    Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
    J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.
    Costa VL; Henrique R; Ribeiro FR; Pinto M; Oliveira J; Lobo F; Teixeira MR; Jerónimo C
    BMC Cancer; 2007 Jul; 7():133. PubMed ID: 17645803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells.
    Krop IE; Sgroi D; Porter DA; Lunetta KL; LeVangie R; Seth P; Kaelin CM; Rhei E; Bosenberg M; Schnitt S; Marks JR; Pagon Z; Belina D; Razumovic J; Polyak K
    Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9796-801. PubMed ID: 11481438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer.
    Hoque MO; Begum S; Topaloglu O; Jeronimo C; Mambo E; Westra WH; Califano JA; Sidransky D
    Cancer Res; 2004 Aug; 64(15):5511-7. PubMed ID: 15289362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
    Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
    Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors.
    Parrella P; Poeta ML; Gallo AP; Prencipe M; Scintu M; Apicella A; Rossiello R; Liguoro G; Seripa D; Gravina C; Rabitti C; Rinaldi M; Nicol T; Tommasi S; Paradiso A; Schittulli F; Altomare V; Fazio VM
    Clin Cancer Res; 2004 Aug; 10(16):5349-54. PubMed ID: 15328171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
    Sebova K; Zmetakova I; Bella V; Kajo K; Stankovicova I; Kajabova V; Krivulcik T; Lasabova Z; Tomka M; Galbavy S; Fridrichova I
    Cancer Biomark; 2011-2012; 10(1):13-26. PubMed ID: 22297548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promoter hypermethylation profile of ovarian epithelial neoplasms.
    Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
    Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
    Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
    Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers.
    Chen ST; Lin SY; Yeh KT; Kuo SJ; Chan WL; Chu YP; Chang JG
    Int J Mol Med; 2004 Oct; 14(4):577-82. PubMed ID: 15375584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
    Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
    J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
    Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
    Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
    Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
    Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma.
    Schagdarsurengin U; Wilkens L; Steinemann D; Flemming P; Kreipe HH; Pfeifer GP; Schlegelberger B; Dammann R
    Oncogene; 2003 Mar; 22(12):1866-71. PubMed ID: 12660822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
    Wang L; Hoque A; Luo RZ; Yuan J; Lu Z; Nishimoto A; Liu J; Sahin AA; Lippman SM; Bast RC; Yu Y
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3660-6. PubMed ID: 14506155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications.
    Hu XC; Wong IH; Chow LW
    Oncol Rep; 2003; 10(6):1811-5. PubMed ID: 14534701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.
    Padar A; Sathyanarayana UG; Suzuki M; Maruyama R; Hsieh JT; Frenkel EP; Minna JD; Gazdar AF
    Clin Cancer Res; 2003 Oct; 9(13):4730-4. PubMed ID: 14581343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.